{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T20:48:40Z","timestamp":1784234920292,"version":"3.55.0"},"reference-count":35,"publisher":"Informa UK Limited","issue":"8","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Investigational Drugs"],"published-print":{"date-parts":[[2021,8,3]]},"DOI":"10.1080\/13543784.2021.1941863","type":"journal-article","created":{"date-parts":[[2021,6,16]],"date-time":"2021-06-16T02:21:47Z","timestamp":1623810107000},"page":"803-811","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":25,"title":["Asciminib: an investigational agent for the treatment of chronic myeloid leukemia"],"prefix":"10.1080","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1163-6162","authenticated-orcid":false,"given":"Massimo","family":"Breccia","sequence":"first","affiliation":[{"name":"Department of Translational and Precision Medicine, Az. Policlinico Umberto I-Sapienza University, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gioia","family":"Colafigli","sequence":"additional","affiliation":[{"name":"Department of Translational and Precision Medicine, Az. Policlinico Umberto I-Sapienza University, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilia","family":"Scalzulli","sequence":"additional","affiliation":[{"name":"Department of Translational and Precision Medicine, Az. Policlinico Umberto I-Sapienza University, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Martelli","sequence":"additional","affiliation":[{"name":"Department of Translational and Precision Medicine, Az. Policlinico Umberto I-Sapienza University, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2021,6,24]]},"reference":[{"key":"e_1_3_5_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1609324"},{"key":"e_1_3_5_4_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.00603"},{"key":"e_1_3_5_5_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.66.2866"},{"key":"e_1_3_5_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-0776-2"},{"key":"e_1_3_5_7_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx219"},{"key":"e_1_3_5_8_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.64.8899"},{"key":"e_1_3_5_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2016.5"},{"key":"e_1_3_5_10_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.74.7162"},{"key":"e_1_3_5_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2015.261"},{"key":"e_1_3_5_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2016.104"},{"key":"e_1_3_5_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-0842-9"},{"key":"e_1_3_5_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2016.246"},{"key":"e_1_3_5_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/nchembio760"},{"key":"e_1_3_5_16_1","doi-asserted-by":"publisher","DOI":"10.1021\/ja101837n"},{"key":"e_1_3_5_17_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature21702"},{"key":"e_1_3_5_18_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.8b01040"},{"key":"e_1_3_5_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2020.106458"},{"key":"e_1_3_5_20_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1902328"},{"key":"e_1_3_5_21_1","doi-asserted-by":"crossref","unstructured":"Mauro MJ Kim DW Cortes J et al. Combination of asciminib plus nilotinib (NIL) or dasatinib (DAS) in patients (pts) with chronic myeloid leukemia (CML): results from a phase 1 study. EHA 2019; S884","DOI":"10.1097\/01.HS9.0000561816.04574.8b"},{"key":"e_1_3_5_22_1","doi-asserted-by":"crossref","unstructured":"Cortes J Lang F Kim DW et al. Combination therapy using asciminib plus imatinib (ima) in patients with chronic myeloid leukemia (CML): results from a phase 1 study. EHA 2019; S883","DOI":"10.1097\/01.HS9.0000561812.22500.d8"},{"key":"e_1_3_5_23_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-139677"},{"key":"e_1_3_5_24_1","unstructured":"Hughes T Mauro MJ Kim D et al. Asciminib in heavily pretreated patients with Ph+CML-CP sensitive to TKI therapy. EHA 2020: S170"},{"issue":"1","key":"e_1_3_5_25_1","first-page":"LBA","article-title":"Efficacy and safety results from ASCEMBL, a multicenter, open-label, phase 3 study of asciminib, a first-in-class STAMP inhibitor, vs bosutinib in patients with chronic myeloid leukemia in chronic phase previously treated with > 2 tyrosine kinase inhibitors","volume":"136","author":"Hochhaus A","year":"2020","unstructured":"Hochhaus A, Boquimpani C, Rea D, et al. Efficacy and safety results from ASCEMBL, a multicenter, open-label, phase 3 study of asciminib, a first-in-class STAMP inhibitor, vs bosutinib in patients with chronic myeloid leukemia in chronic phase previously treated with > 2 tyrosine kinase inhibitors. Blood. 2020;136(s1):LBA\u20134.","journal-title":"Blood"},{"key":"e_1_3_5_26_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.264"},{"key":"e_1_3_5_27_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.24393"},{"key":"e_1_3_5_28_1","unstructured":"ClinicalTrials.gov. Frontline asciminib combination in chronic phase CML (CMLXI). CML (CMLXI). cited 2021 Jan 21. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03906292"},{"key":"e_1_3_5_29_1","unstructured":"ClinicalTrials.gov. ABL001 for the treatment of chronic myeloid leukemia in patients who are on therapy with tyrosine kinase inhibitor. cited 2021 Jan 21. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04216563"},{"key":"e_1_3_5_30_1","unstructured":"ClinicalTrials.gov. Asciminib in monotherapy for chronic myeloid leukemia in chronic phase (CML-CP) with and without T315I mutation (AIM4CML). cited 2021 Jan 21. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04666259"},{"key":"e_1_3_5_31_1","unstructured":"ClinicalTrials.gov. Study of efficacy and safety of asciminib in combination with imatinib in patients with chronic myeloid leukemia in chronic phase (CML-CP). cited 2021 Jan 21. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03578367"},{"key":"e_1_3_5_32_1","unstructured":"ClinicalTrials.gov. Pharmacokinetics study of asciminib in subjects with impaired renal function compared to matched healthy volunteers. cited 2021 Jan 21. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03605277"},{"key":"e_1_3_5_33_1","unstructured":"ClinicalTrials.gov. A trial to evaluate the pharmacokinetics of ABL001 in healthy and hepatic impaired subjects. cited 2021 Jan 21. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02857868"},{"key":"e_1_3_5_34_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00420-8"},{"key":"e_1_3_5_35_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.49.9020"},{"key":"e_1_3_5_36_1","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.3071"},{"key":"e_1_3_5_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2019.08.004"}],"container-title":["Expert Opinion on Investigational Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13543784.2021.1941863","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,26]],"date-time":"2024-11-26T08:46:53Z","timestamp":1732610813000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/13543784.2021.1941863"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,24]]},"references-count":35,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2021,8,3]]}},"alternative-id":["10.1080\/13543784.2021.1941863"],"URL":"https:\/\/doi.org\/10.1080\/13543784.2021.1941863","relation":{},"ISSN":["1354-3784","1744-7658"],"issn-type":[{"value":"1354-3784","type":"print"},{"value":"1744-7658","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,24]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieid20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieid20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2021-02-09","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-06-08","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-06-24","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}